Loading
A phase 1/2 trial of Capmatinib and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05488314 by Janssen Research & Development, LLC, with 57 participants enrolled, started 2022-12-13 and due to reach its primary completion in 2027-04-28. Interventions recorded: Capmatinib and Amivantamab.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.